MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
6.40
+0.01
+0.16%
After Hours: 6.40 0 0.00% 17:00 05/31 EDT
OPEN
6.39
PREV CLOSE
6.39
HIGH
6.52
LOW
6.25
VOLUME
533.34K
TURNOVER
0
52 WEEK HIGH
7.32
52 WEEK LOW
2.570
MARKET CAP
496.16M
P/E (TTM)
-5.5541
1D
5D
1M
3M
1Y
5Y
JMP Securities Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
TipRanks · 05/25 04:55
Ocular Therapeutix: I Still Don't See The Need
Seeking Alpha · 05/18 17:00
Ocular Therapeutix (OCUL) Gets a Buy from Robert W. Baird
TipRanks · 05/11 15:55
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation
NASDAQ · 05/10 14:24
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Olema Pharmaceuticals (OLMA) and Cognition Therapeutics (CGTX)
TipRanks · 05/10 12:02
Expert Ratings for Ocular Therapeutix
Benzinga · 05/09 20:02
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $10
Benzinga · 05/09 14:52
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and EQRx, Inc. (EQRX)
TipRanks · 05/09 14:50
More
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Its earlier stage development assets include: axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy; travoprost intracameral implant (OTX-TIC), is under Phase II clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and dexamethasone intracanalicular insert (OTX-DED), for the short-term treatment of the signs and symptoms of dry eye disease; and cyclosporine intracanalicular insert (OTX-CSI), for the chronic treatment of dry eye disease, both of which have completed Phase II clinical trials.

Webull offers kinds of Ocular Therapeutix Inc stock information, including NASDAQ:OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.